Amrad halts buyback during Avexa spin-out

By Melissa Trudinger
Thursday, 01 July, 2004

Amrad (ASX:AML) has halted its share buy-back program while it readies itself to spin out its anti-infectives program.

The process will allow the company to calculate the entitlements of shareholders so that shares can be distributed into the new company, Avexa, during the demerger. Amrad shareholders will receive shares in Avexa on a pro rata basis according to their holdings in Amrad on the record date for the offer.

The Amrad share buy-back program will continue once the record date has passed, the company said.

Related News

Algae unlocks a more ethical way to grow cells

Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...

Oral drug shows promise for treating Barth syndrome

An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...

New route into cells found for gene therapy viruses

Scientists have identified a previously unknown gateway into human cells — a receptor...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd